The Year in Cardiology 2013: Acute Coronary Syndromes Early Diagnosis and Risk Stratification

Patients presenting with acute coronary syndromes (ACS) remain a challenging medical condition with potential in improving outcome despite major advances over recent years. During the year 2013, progress has been made with respect to a better understanding of the underlying mechanisms and diagnosing ACS. In addition, new studies provided fundamental insights the optimal management, particularly with respect to the best antithrombotic regimen.

[1]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[2]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[3]  Deepak L. Bhatt,et al.  Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data , 2013, The Lancet.

[4]  M. Böhm,et al.  Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. , 2013, European heart journal.

[5]  Sunil V. Rao,et al.  Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. , 2013, JAMA.

[6]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[7]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[8]  A. Rosengren,et al.  Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. , 2013, European heart journal.

[9]  L. Wallentin,et al.  New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis , 2013, European heart journal.

[10]  G. Niccoli,et al.  Severity of coronary atherosclerosis in patients with a first acute coronary event: a diabetes paradox. , 2013, European heart journal.

[11]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[12]  Marek Malik,et al.  Respiratory rate predicts outcome after acute myocardial infarction: a prospective cohort study. , 2013, European heart journal.

[13]  T. Lehtimäki,et al.  Bacterial Signatures in Thrombus Aspirates of Patients With Myocardial Infarction , 2013, Circulation.

[14]  L. Neyses,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[15]  Doris A Taylor,et al.  Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. , 2012, JAMA.

[16]  P. Armstrong,et al.  Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.

[17]  F. Van de Werf,et al.  Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. , 2013, European heart journal.

[18]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[19]  S. Pocock,et al.  Bivalirudin started during emergency transport for primary PCI. , 2013, The New England journal of medicine.

[20]  E. Vicaut,et al.  Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. , 2013, The New England journal of medicine.

[21]  Deepak L. Bhatt,et al.  Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial , 2013, The Lancet.

[22]  A. Jaffe,et al.  Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). , 2013, Journal of the American College of Cardiology.

[23]  V. Jeevanantham,et al.  Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac Parameters: A Systematic Review and Meta-Analysis , 2012, Circulation.